Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
64
resultados
Última actualización
22/01/2026 [07:35:00]
Resultados 25 a 50 de 64
Resumen de: US2025389734A1
A method for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases, comprising determining the level of TPK1 protein in a sample from a subject, wherein a decrease in the level of TPK1 protein compared to a reference value indicates that the subject has Alzheimer's disease. Methods, compositions, test strips, test cards and/or kits for distinguishing or differentially diagnosing Alzheimer's disease from other neurodegenerative diseases by detecting a biomarker, wherein the methods, compositions, test strips, test cards and/or kits can specifically diagnose Alzheimer's disease.
Resumen de: US2025388967A1
The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Resumen de: US2025389733A1
The current disclosure describes a method to differentiate whether a blood sample belongs to a normal group or a risk group considering isoAsp. The disclosed method comprises: obtaining a first set of test blood samples and a second set of blood samples that are considered belonging to a normal (control) group; obtaining plasma from said blood samples; measuring the relative abundance of anti-isoaspartate antibodies in each plasma sample; measuring the occupancy of isoaspartate residue in a representative HSA sequence location in each plasma sample; based on the distributions in the set of normal plasma samples of the relative abundances of anti-isoaspartate antibodies and of the occupancies of isoaspartate residues in a representative HSA sequence location, establishing a statistical model for the probability for a given plasma sample to be a normal sample; attributing every plasma test sample to either normal or risk group based on the maximum likelihood according to their measured values and said statistical model.
Resumen de: CN120329431A
The present invention provides a method of measuring the amount of mono-or poly-phosphorylated p217 + tau protein in a sample. Also provided are methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of treatment of tauopathies, and methods of determining whether a subject is suitable for anti-p217 + tau antibody therapy. Antibodies for use in the methods and kits comprising the antibodies are also described.
Resumen de: CN120660001A
A method of determining the extent of a central nervous system (CNS)-specific neurological disease in a subject includes collecting a sample of a biological fluid of the subject and measuring the amount of a first biomarker or a metabolite thereof or a corresponding mRNA in the sample by a dry spot or microfluidic device. The body fluid is blood capillary blood or saliva, and is suitable for on-site, hospital and family environments due to the advantage of convenient collection. The method has general practicability in the aspects of diagnosis, nursing and management of brain specific abnormal nerve diseases, and is particularly suitable for traumatic brain injury (TBI), Alzheimer's disease (AD) (induced by TBI) and Alexander disease (a disease of white matter deterioration caused by GFAP mutation).
Resumen de: WO2025259709A1
The present disclosure provides methods of screening for, identifying and using a Gi-GPCR agonist for a CNS disorder. The CNS disorder can be any disorder in which astrocyte morphology and/or astrocyte tissue support are altered or compromised (e.g., OCD, Alzheimer's disease, or Huntington's disease). Provided herein are methods of screening for and identifying Gi-GPCR agonist ex vivo based on assessment of astrocyte morphology and/or Gi-GPCR activation (e.g., wherein the Gi-GPCR is GPR3711, S1PR1, EDNRB, GRM3, or AD0RA2A). Also provided herein are methods of identifying a therapeutic agent for the treatment of a CNS disorder in vivo at least in part based on its effect on astrocyte morphology and/or Gi-GPCR activation. Also provided herein are methods for the treatment or prevention of a CNS disorder comprising administering to a subject a Gi-GPCR (e.g., GPR3711, S1PR1, EDNRB, GRM3, or AD0RA2A) agonist.
Resumen de: WO2025260029A1
Disclosed herein are immunoassay methods of measuring amyloid β protofibril levels in biological samples and diagnostic and therapeutic uses thereof. Methods disclosed herein use a single molecule counting instrument for detection. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: WO2025256506A1
Provided herein are plasma protein markers associated with neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD), diagnostic and treatment/management methods for these conditions, as well as kits for diagnosing and/or treating/monitoring these conditions. Machine learning systems and methods are also provided for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels.
Resumen de: WO2025258826A1
According to embodiments of the present disclosure, disclosed is a method for determining the possibility of Alzheimer's disease by using a brain organoid of a user, the method comprising the steps of: receiving, by a determination server, a first factor value measured by using a first method for a brain organoid cultured from a user's stem cells; determining whether the first factor value of the brain organoid exceeds a preset first reference value; if the first factor value exceeds the first reference value, determining that the user's possibility of developing slow-onset Alzheimer's disease is high; if the first factor value is less than or equal to the first reference value, obtaining a second factor value measured by applying a second method to the brain organoid of the user; and determining, on the basis of the second factor value, the user's possibility of developing rapid-onset Alzheimer's disease.
Resumen de: KR20250175781A
본 발명은 smp30의 알츠하이머병 치료 또는 수명 및 건강수명의 연장 용도에 관한 것이다. 본 발명에 따른 smp30은 알츠하이머병 질환 내 인산화된 타우 단백질의 감소 뿐만 아니라, 운동 능력 증가, 산화 스트레스에 대한 저항성 증가, 항산화 효과 증가, 굶주림 스트레스 저항성 증가 및 노화 감소에 대한 효과를 가져, 알츠하이머병 치료, 알츠하이머병 치료제 후보물질 발굴, 및 수명 및 건강수명 연장 또는 개선에 활용이 가능하다.
Resumen de: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Resumen de: EP4663754A2
The invention relates to a panel of biomarkers comprising tau or one or more fragments thereof.
Resumen de: AU2024274218A1
The present invention refers to the use of a biomarker for measuring the efficacy or effectiveness of treatments for neurodegenerative diseases, in particular, for Alzheimer's disease.
Resumen de: AU2024235526A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US2025377367A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Resumen de: US2025376508A1
The disclosure generally relates to immunoglobulin and/or antigen binding fragment(s) that specifically bind to post-synaptic density (PSD95) phosphorylated at threonine (19), at (serine 25), and/or at both threonine (19) and serine (25), as well as corresponding expression vectors and host cells, and methods of diagnosing and kit using such immunoglobulin and/or antigen binding fragment(s) that specifically bind to PSD95 phosphorylated at threonine (19), at serine (25), and/or at both threonine (19) and serine (25).
Resumen de: WO2025255493A2
Methods and assays for identifying Alzheimer's disease in a subject include determining an amount in the biological sample of one or more biomarkers selected from glucagon-like peptide 1 receptor (GLP-1R), C2 calcium dependent domain containing 4C (C2CD4C), low-density lipoprotein receptor adapter protein 1 (LDLRAP1), nuclear factor erythroid 2-related factor 2 (NFE2L2), doublecortin (DCX), sequestosome (SQSTM1), nuclear factor κB1 (NFκB1), transcription factor RelB (RelB), and combinations thereof. Methods and assays for identifying chronic hydrocephalus in a subject are also provided and include determining an amount in a biological sample of RelB and/or FCGBP. Screening methods are further provided and include contacting a cell with an effective amount of a test compound and then detecting an expression level or activity of the biomarkers.
Resumen de: WO2025253337A2
The present disclosure provides binding proteins that target tau, as well as bispecific binding proteins that target tau and a central nervous system protein (e.g., transferrin receptor 1). Also provided is the use of these binding proteins to treat tauopathies.
Resumen de: WO2024161163A2
Declining cerebral blood flow leads to chronic cerebral hypoperfusion which can induce neurodegenerative disorders, such as vascular dementia. The reduced energy supply of the brain impairs mitochondrial functions that could trigger further damaging cellular processes. Altered levels of protein biomarkers are discloses to be useful in the diagnosis of vascular dementia.
Resumen de: AU2024235526A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: US2022365093A1
Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: US2025368729A1
Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.
Resumen de: US2025369989A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Nº publicación: KR20250169354A 02/12/2025
Solicitante:
리전츠오브더유니버스티오브미네소타
Resumen de: WO2024220662A2
This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
BOPI
Sede Electrónica
